Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19

Background: There are currently no FDA-approved medications for the treatment of COVID-19. At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period. Me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:medRxiv
Main Authors: Rhodes, Nathaniel James, Dairem, Atheer, Moore, William, Shah, Anooj, Postelnick, Michael J, Badowski, Melissa E., Michienzi, Sarah M, Borkowski, Jaime L, Polisetty, Radhika S, Fong, Karen, Spivek, Emily S, Beardsley, James R, Hale, Cory M, Pallotta, Andrea M, Srinivas, Pavithra, Schulz, Lucas T
Formato: Artigo
Idioma:Inglês
Publicado em: Cold Spring Harbor Laboratory 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7302293/
https://ncbi.nlm.nih.gov/pubmed/32577687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.06.03.20121558
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados